Thus, inhibiting the inflammatory mediators (IL-6, G-CSF) or downstream MEK signaling prevented chemotherapy (DTX)-induced breast cancer dormancy awakening and ameliorated a potentially tumor immunosuppressive microenvironment. This evidence concerns the gene IL6 and breast carcinoma.